BMP-2: bone morphogenetic protein 2
The osteoinductive growth factor that moved from a laboratory curiosity to approved clinical use — and the lessons of its dosing.
Bone morphogenetic proteins were discovered through a striking observation: demineralised bone matrix implanted into muscle induced new bone to form there. The proteins responsible turned out to belong to the TGF-β superfamily, and BMP-2 became the most studied of them.
BMP-2 is osteoinductive: it signals mesenchymal stem cells to commit to the osteoblast lineage. Recombinant human BMP-2 is among the few growth factors to reach approved clinical use in bone regeneration, alongside BMP-7.
Its clinical history is also the field's cautionary tale about dose. The recombinant protein has a short half-life, so supraphysiologic amounts were delivered on a collagen carrier to sustain an effect — and reported complications including ectopic bone formation and swelling followed. The response has been to focus less on how much and more on where, how long, and in what sequence, which is the agenda of Controlled release kinetics and Growth factor delivery.
Related articles
- BoneBMP-7: osteogenic protein-1The other clinically applied bone morphogenetic protein, and what comparing it with BMP-2 reveals.
- SignalingGrowth factor deliveryPotent, unstable, and short-lived — why delivering growth factors is harder than choosing them.
- SignalingControlled release kineticsGetting the right signal to the right place at the right time — for the right duration.
- SignalingTGF-β signalingThe superfamily containing the BMPs — and a signal whose effect depends entirely on context.
- BoneOsteoblasts and osteoclastsThe two opposing cell types whose balance determines whether bone is built or lost.
- BoneBone remodelingThe continuous cycle of resorption and formation that rebuilds the skeleton throughout life.